Media Relations Contact Ashleigh Koss Tel: +1 (908) [email protected], Quentin VivantTel. Regeneron Media Relations Contact Daren Kwok Tel. : +1 (781) 264-1091 [email protected] Investor Relations - Paris Eva Schaefer-Jansen Arnaud Delepine Yvonne Naughton Investor Relations – North America Felix Lauscher Fara Berkowitz Suzanne Greco KY1005 demonstrated a consistent treatment effect versus placebo across various key endpoints, including in the Eczema Area and Severity Index (EASI) and additional objective clinical measures. Sanofi Investor Relations Contacts North America. Sanofi … Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently. Karl Rotthier, 53 years old, is a seasoned leader with a strong API business experience. The U.S. Food and Drug Administration (FDA) granted a Priority Review with a target … He was most recently the Chief Executive Officer of Centrient Pharmaceuticals, and had the opportunity throughout his 29-years international career in the Netherands, Germany, Austria, Belgium and Singapore, to also drive operational carve-outs and spin-offs. EUROAPI will employ 3,200 skilled employees and be headquartered in France. Sally Bain. By continuing to browse this website, you agree to the use of such cookies. Suzanne Greco . Sanofi Media Relations Contact Sally Bain Tel. : +33 (0)1 53 77 45 45. ir@sanofi… Arnaud Delepine. : +1 (781) 264-1091 [email protected] . Sanofi, Empowering Life Media Relations Contacts Sally Bain Tel. This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Sanofi expects to complete the acquisition in the first half of 2021. Sanofi Investor Relations – Contacts North America Felix Lauscher Fara Berkowitz Suzanne Greco. By continuing to browse this website, you agree to the use of such cookies. Sanofi Investor Relations Contacts Paris Eva Schaefer-Jansen Arnaud Delepine Yvonne Naughton Sanofi Investor Relations Contacts North America Felix Lauscher Fara Berkowitz Suzanne Greco IR main line: Tel. Sanofi Contacts: Media Relations. : +33 (0)1 53 77 45 45 [email protected] Kymab Media UK Consilium Strategic Communications Mary-Jane Elliott / Sukaina Virji / Melissa Gardiner [email protected] Tel: +44 (0) 20 3709 5700 Sanofi … Kymab’s IntelliSelect Transgenic platforms contain a full diversity of human antibodies, making them the most comprehensive antibody platforms available. Sanofi … Sanofi Investor Relations Contacts Paris. Paris – January 12th, 2021 - Sanofi chooses EUROAPI as the name for the future leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients (API). Investor Relations Main Line. Sanofi Forward … EUROAPI will have significant competitive strengths, including a broad portfolio of 200 APIs with both volume and niche products, high standards of quality and industrial means, competitive pricing and technologies across Europe, and will leverage an extensive commercial network covering more than 80 countries. : +33 (1) 53 77 45 45 ir@sanofi… “This acquisition aligns with our strategy of targeting fundamentally important disease pathways.  We believe that OX40L, a key immune regulator, has the potential to rebalance the immune system without suppressing it, providing a promising new approach to treating a range of immune-mediated diseases,” said John Reed, M.D. Tel. Karl will lead the creation of EUROAPI together with the new company Management Team towards its growth ambitions. PARIS and CAMBRIDGE, UK – January 11, 2021 – Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, have entered into an agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The novel mechanism of action may provide treatment for patients with suboptimal responses to available therapies,” said Paul Hudson, Sanofi Chief Executive Officer. Sanofi expects to complete the acquisition in the first half of 2021.Â. IR main line: Tel. The closing of the transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions. To provide the optimal conditions for success, Sanofi intends the new company to be debt free in order to maximize its future … : +1 781 264 1091 . 1 Subject to consultation with social partners and works councils, 2 Source: company estimates based on comparison with data published in annual reports of major API companies, 3 Source: Future growth estimate based on expert interviews and Technavio Report “Active Pharmaceutical Ingredients, Market by Manufacturing Type and Geography – Forecast and Analysis 2020-2024”, Dec. 2019. Yvonne Naughton. Felix Lauscher. The data were shared during a late-breaking presentation at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress and formed the basis of regulatory submissions in the U.S. and European Union (EU). Sanofi is fully committed to the new company’s success, including by establishing a long-term customer relationship with EUROAPI and holding a minority stake of approximately 30% in it. Fara Berkowitz. “The Kymab acquisition adds KY1005 to our dynamic pipeline, a potential first-in-class treatment for a range of immune and inflammatory diseases. Sanofi plans to finance the transaction with cash on hand. Building on a strong industrial legacy built over decades and broad expertise and experience, EUROAPI would help secure a greater stability in supplying quality drugs to millions of patients worldwide.”. Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L, *Continues to build on Sanofi’s leading presence in immunology aligned with strategy to pursue best-in-class treatments in defined areas. Addressing recent increasing medicine shortages that critically impact patient care, EUROAPI will ensure additional API supply capacities for Europe and beyond, and help balancing the industry’s heavy reliance on API sourced from other regions. : +1 (908) 205-2572 [email protected] Sanofi Investor Relations Contacts Paris Eva Schaefer-Jansen Arnaud Delepine Yvonne Naughton Sanofi Investor Relations Contacts North America Felix Lauscher Fara Berkowitz Suzanne Greco IR main line: Tel. Kymab and IntelliSelect are trademarks of Kymab Limited. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many … Philippe Luscan, Executive Vice President, Global Industrial Affairs at Sanofi, said: “We are very pleased today to unveil EUROAPI and welcome Karl to lead this future industry champion, as it gives further substance to our ambitious project. Under the terms of the transaction, Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. Eva Schaefer-Jansen. The acquisition also provides Sanofi with access to new antibody technologies and research capabilities. [email protected] Regeneron Media Relations Contact Daren Kwok Tel. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the  ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer. Tel. For more information on Kymab please see http://www.kymab.com. Sanofi IR main line: Tel. Sanofi is fully committed to the new company’s success, including by establishing a long-term customer relationship with EUROAPI and holding a minority stake of approximately 30% in it. “With its significant global resources, we believe Sanofi is the perfect partner to progress Kymab’s pipeline of products and the merger will expedite the time it takes for our novel therapies to get to patients.”, KY1005: Promising antibody for inflammatory disorders. Sanofi is fully committed to the new company’s success, including by establishing a long-term customer relationship with EUROAPI and holding a minority stake of approximately 30% in it. Sanofi Investor Relations Contacts Paris Eva Schaefer-Jansen Arnaud Delepine Yvonne Naughton. Suzanne Greco IR main line: Tel. Investor Relations Sanofi Investor Relations – Contacts Paris Eva Schaefer-Jansen Arnaud Delepine Yvonne Naughton. KY1005 binds to OX40-Ligand and has the potential to treat a wide variety of immune-mediated diseases and inflammatory disorders. Fara Berkowitz. Active pharmaceutical ingredients or APIs are the chemicals or biologicals which have a beneficial therapeutic effect in a medicine. This website uses cookies to track its audience and improve its content. : +1 (781) 264-1091 [email protected]. : +33 (0)1 53 77 45 45 [email protected] Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Sanofi Investor Relations – Contacts Paris. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. Arnaud Delepine. Sanofi Contacts: Media Relations. This website uses cookies to track its audience and improve its content. Sanofi IR main line: Tel: +33 (0)1 53 77 45 45 : +33 (0)1 53 77 45 45 ir@sanofi… [email protected]. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. Tel: +1 (781) 264-1091. Sanofi IR … These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Sanofi Media Relations Contact Sally Bain Tel. Tel. Sally Bain . This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. Sanofi Investor Relations Contacts Paris Eva Schaefer-Jansen Arnaud Delepine Yvonne Naughton. *About Active Pharmaceutical Ingredients (API). The transaction will result in Sanofi having full global rights to KY1005, a fully human monoclonal antibody that has a novel mechanism of action. Kymab’s pipeline also includes the oncology asset KY1044, an ICOS agonist monoclonal antibody, currently in early Phase 1/2 development as monotherapy and in combination with an anti-PD-L1. The Acceptance Period commences at 09.00 hours CET, on 15 February 2021 and will, unless extended, expire at 17.40 hours CET on 12 April 2021. : +33 (0)1 53 77 45 45 [email protected] Forward-looking statements are statements that are … Sanofi Investor Relations Contacts North America Felix Lauscher Fara Berkowitz Suzanne Greco. Click here for more information on cookies. Sanofi also announces the appointment of Karl Rotthier as the EUROAPI future Chief Executive Officer, effective January 18th. It will rank number 1 in small molecules API, and number 2 on the global API market2. “We understand from our ongoing work in debilitating immunological diseases how critical it is to find the right treatment for each patient. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. : +1 (914) 847 1328 [email protected]. IR main line: Tel. [email protected] . This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 4 paragraph 1, Article 10 paragraph 1 and 3, and Article 18 paragraph 3 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen … Sanofi Investor Relations – Contacts North America. Forward-looking statements are statements that are not historical facts. Investor Relations Sanofi Investor Relations – Contacts Paris Eva Schaefer-Jansen Arnaud Delepine Yvonne Naughton. [email protected] Yvonne Naughton. Eva Schaefer-Jansen. Suzanne Greco IR main line: Tel. Sanofi Investor Relations Contacts North America Felix Lauscher Fara Berkowitz Suzanne Greco. The project announced by Sanofi in February 2020, consists of creating a standalone company which will combine Sanofi’s API commercial and development activities with six of its European production sites: Brindisi (Italy), Frankfurt Chemistry (Germany), Haverhill (UK), St Aubin les Elbeuf (France), Újpest (Hungary) and Vertolaye (France). Sanofi Investor Relations Contacts North America Felix Lauscher Fara Berkowitz Suzanne Greco IR main line: Tel. We look forward to rapidly developing this investigational medicine.”, “The agreement is a testament to the commitment, drive and expertise of the entire Kymab team and we are pleased to receive this endorsement from Sanofi,” added Simon Sturge, Chief Executive Officer, Kymab. : +33 (0)1 53 77 45 45 [email protected] Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as … : +1 (781) 264-1091. : +33 (0)1 53 77 45 45 . Click here for more information on cookies, Karl Rotthier joins Sanofi as EUROAPI Chief Executive Officer and further lead the creation of this new Europe-based industry champion, EUROAPI will help securing significant API manufacturing and supply capacities that are critical for patients in Europe and beyond, An IPO on Euronext Paris will be evaluated for 2022 - subject to market conditions. Felix Lauscher. Suzanne Greco. Weil, Gotshal & Manges LLP is acting as Sanofi’s legal counsel. A planned IPO on Euronext Paris would be evaluated with a decision expected by 2022, subject to market conditions. To provide the optimal conditions for success, Sanofi intends the new company to be debt free in order to maximize its future investment capacities.”, Karl Rotthier, future CEO of EUROAPI emphasizes: “I am particularly delighted to join EUROAPI and look forward to working with my colleagues in creating an agile, stand-alone company, able to unlock its growth potential in a market sustainably growing at a pace of 6% per year3. In August 2020, Kymab announced that KY1005 met both primary endpoints in a Phase 2a trial studying moderate to severe atopic dermatitis patients whose disease is inadequately controlled with topical corticosteroids. : +1 (914) 847 1328 [email protected]: Sanofi Investor Relations Contacts Paris Eva Schaefer-Jansen Arnaud Delepine Yvonne Naughton Sanofi Investor Relations Contacts North America Felix Lauscher Fara Berkowitz Suzanne Greco Sanofi … : +33 (0)1 53 77 45 45 [email protected] . These are the essential molecules used in the composition and the production of any drug. Sanofi Investor Relations – Contacts North America Felix Lauscher Fara Berkowitz Suzanne Greco Sanofi …